B. Riley Lowers Perspective Therapeutics (NYSEAMERICAN:CATX) Price Target to $11.00

Perspective Therapeutics (NYSEAMERICAN:CATX) had its price objective lowered by equities researchers at B. Riley from $12.00 to $11.00 in a research note issued on Tuesday,Benzinga reports. The firm presently has a “buy” rating on the stock. B. Riley’s price objective points to a potential upside of 371.09% from the stock’s previous close.

Several other equities analysts also recently weighed in on CATX. HC Wainwright reaffirmed a “buy” rating and issued a $10.00 target price on shares of Perspective Therapeutics in a research report on Friday, October 3rd. BTIG Research assumed coverage on shares of Perspective Therapeutics in a research report on Friday, October 10th. They issued a “buy” rating and a $14.00 price target for the company. Finally, Wedbush restated an “outperform” rating and issued a $11.00 price target on shares of Perspective Therapeutics in a research note on Tuesday, November 11th. Four equities research analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and one has given a Hold rating to the stock. According to data from MarketBeat, the company has an average rating of “Buy” and an average price target of $11.78.

Perspective Therapeutics Stock Performance

Shares of CATX stock traded up $0.13 during trading hours on Tuesday, hitting $2.34. The company had a trading volume of 1,159,433 shares, compared to its average volume of 1,047,579. The company has a debt-to-equity ratio of 0.01, a quick ratio of 15.09 and a current ratio of 15.09. The company’s fifty day moving average is $3.22 and its 200 day moving average is $3.32. Perspective Therapeutics has a fifty-two week low of $1.60 and a fifty-two week high of $7.08.

Perspective Therapeutics (NYSEAMERICAN:CATX) last announced its earnings results on Monday, November 10th. The company reported ($0.35) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.02). Perspective Therapeutics had a negative net margin of 7,688.50% and a negative return on equity of 33.37%. The firm had revenue of $0.21 million during the quarter, compared to analysts’ expectations of $0.21 million. Equities research analysts anticipate that Perspective Therapeutics will post -0.88 earnings per share for the current year.

Institutional Trading of Perspective Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in CATX. Vanguard Group Inc. boosted its stake in Perspective Therapeutics by 5.0% during the 3rd quarter. Vanguard Group Inc. now owns 3,437,865 shares of the company’s stock worth $11,792,000 after purchasing an additional 163,532 shares during the period. Affinity Asset Advisors LLC boosted its stake in shares of Perspective Therapeutics by 71.1% in the first quarter. Affinity Asset Advisors LLC now owns 2,224,196 shares of the company’s stock valued at $4,738,000 after buying an additional 924,196 shares in the last quarter. Nicholson Wealth Management Group LLC grew its holdings in shares of Perspective Therapeutics by 0.3% in the 2nd quarter. Nicholson Wealth Management Group LLC now owns 1,614,283 shares of the company’s stock worth $5,553,000 after acquiring an additional 5,000 shares during the period. Geode Capital Management LLC increased its position in shares of Perspective Therapeutics by 15.8% in the second quarter. Geode Capital Management LLC now owns 1,382,814 shares of the company’s stock valued at $4,758,000 after buying an additional 188,887 shares in the last quarter. Finally, Nuveen LLC acquired a new position in Perspective Therapeutics during the first quarter worth about $2,647,000. Institutional investors and hedge funds own 54.66% of the company’s stock.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.